logo
The Baseline
18 Aug 2026
Five stocks to buy from analysts this week - August 18, 2026
By Ruchir Sankhla

1. Lenskart Solutions: 

Motilal Oswal reiterates its ‘Buy’ rating on this eyewear retailer, with a target price of Rs 705, an upside of 12.2%. In Q1FY27, Lenskart's revenue grew 43% YoY, driven by strong sales in India and overseas, while higher customer spending on premium eyewear helped net profit reach Rs 221.8 crore. 

Management sees significant room to add stores without hurting sales at existing outlets. Sales from established Indian stores increased 18.3% during the quarter. Lenskart added 132 stores, bringing its global total to 3,459. It has identified more than 6,100 PIN codes where it does not yet have a presence, and plans to open more than 3,000 stores in existing markets. Analysts Aditya Bansal and Avinash Karumanchi note that the company targets all price segments effectively: premium lines generate 20% of sales, while manufacturing efficiencies have made its entry-level Rs 500 range profitable.

Bansal and Karumanchi forecast annual revenue and net profit to grow by 25% and 50%, respectively, over FY27–28. As frame manufacturing moves in-house and supply chains are streamlined, margins should get a boost. The analysts have also raised their FY27–28 operating profit estimates by up to 5%.

2. Fine Organic Industries:

Anand Rathi maintains its ‘Buy’ rating on this chemicals manufacturer, with a target price of Rs 6,000, an upside of 17.8%. In Q1FY27, the company’s revenue grew 18% YoY, led by stronger pricing and robust exports, which made up 60% of sales. Net profit also rose 18%. Analysts Nitesh Dhoot and Tanvi Warekar highlight that Fine Organic protected its profitability by passing rising raw material, power, and transport costs on to customers.

Management expects flat near-term volumes because most factories operate near full capacity. While the Patalganga plant offers extra room, the next major growth driver will be the new Jawaharlal Nehru Port Authority Special Economic Zone (JNPA SEZ) facility, scheduled to start up in late FY28. Fine Organic is also constructing its first manufacturing plant in the US, with the first phase forecasted to be operational in 2027.

Dhoot and Warekar estimate profits to surge from FY28 as new plants start contributing. Fine Organic currently has Rs 1,400 crore in cash and anticipates generating an additional Rs 750 crore over FY27–28. The analysts believe this cash flow will fund the India and US expansion without requiring heavy debt.

3. Akums Drugs & Pharmaceuticals: 

ICICI Securities maintains its ‘Buy’ rating on this pharma major, with a higher target price of Rs 850, implying a 14.1% upside. The company showed solid Q1FY27 results. Revenue grew 13.9% YoY, led by traction in the contract development & manufacturing organisation (CDMO) and domestic branded formulations segments. Net profit soared 57.5%, fueled by inventory destocking and richer margins in trade generics and active pharmaceutical ingredients (APIs).

Management expects sales to increase at a double-digit rate over the next two years. Analysts Abdulkader Puranwala and Nisha Shetty believe growth will be supported by new contracts in Zambia and Europe, with shipments scheduled to begin by Q3FY27. Akums has also acquired Oriflame India’s colour cosmetics manufacturing facilities, enabling it to expand into skincare, cosmetics and wellness products.

The analysts note that exports and higher-value products should improve profitability. Management also anticipates the European and Zambian contracts to earn better margins than its domestic business. Exiting smaller non-core businesses should also support profits. They estimate revenue to grow by around 14.4% annually and net profit by 37.7% annually over FY27 and FY28.

4. Ipca Laboratories: 

Emkay reiterates its ‘Buy’ rating on this pharma manufacturer, with a target price of Rs 1,950, implying a 3.6% upside. Ipca delivered strong Q1FY27 earnings as revenue grew 20.2% YoY, boosted by domestic formulations, generics, and branded products sales. Net profit surged 72.3%, thanks to a high-value product mix. 

Management has raised its FY27 revenue growth target to 15% as demand remains healthy across markets. Sales at Unichem, its US business, are also improving, easing concerns about US growth. Analysts Shashank Krishnakumar and Mohd Suheb Alam highlight plans to invest Rs 700–800 crore to expand manufacturing capacity for finished medicines, biological drugs and key ingredients used to make medicines.

Krishnakumar and Alam believe profitability will improve as higher-value products and exports contribute more to sales. They also expect revenue to rise faster than raw material and employee costs. They forecast revenue to grow by around 10.2% annually and net profit by 16.2% annually over FY27–29.

5. Pitti Engineering: 

Deven Choksey maintains its ‘Buy’ rating on this small-cap electrical equipment manufacturer, with a target price of Rs 1,258, an upside of 21.5%. In Q1FY27, revenue rose 15.9% YoY, thanks to demand across its core businesses. Railways generated 28% of revenue, power generation brought in 15%, and industrial applications contributed 12%.

Management anticipates 17–18% volume growth over the next few years as it targets new businesses in mining, oil & gas, data centres, and specialty industrial markets. A recently completed expansion of sheet metal, machining, and castings production will boost H2FY27 output, supporting its annual revenue target of up to 3,300 crore by FY27. Pitti is also investing Rs 290 crore in a new Hyderabad plant, which is scheduled to start operations in Q1FY30.

Analyst Manik Jain projects profits to rise faster than revenue as Pitti makes more higher-value finished and assembled components. He believes new capacity and better use of existing factories should also support profitability. Jain estimates annual revenue and net profit growth of 14.1% and 26.8%, respectively, over FY27–28. He raised his FY28 earnings estimate by 6% and expects EBITDA margins to reach up to 17.5% by FY28.

 

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)

More from The Baseline
More from Trendlyne Analysis
Recommended